{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:48:50Z","timestamp":1788306530249,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s00198-005-0035-4","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T19:55:34Z","timestamp":1138218934000},"page":"693-703","source":"Crossref","is-referenced-by-count":66,"title":["Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients"],"prefix":"10.1007","volume":"17","author":[{"given":"H.","family":"Dobnig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C.","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Viereck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"35_CR1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581\u2013589","journal-title":"J Bone Miner Res"},{"key":"35_CR2","first-page":"S66","volume":"34","author":"H M\u00f6nkk\u00f6nen","year":"2004","unstructured":"M\u00f6nkk\u00f6nen H, Lehenkari PP, Kellinsalmi M (2004) A new mechanism of action for bisphosphonates: apppi dedicated cytotoxicity of N-BPs. Bone 34:S66\u2013S67","journal-title":"Bone"},{"key":"35_CR3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","volume":"31","author":"EF Eriksen","year":"2002","unstructured":"Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620\u2013625","journal-title":"Bone"},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687\u2013694","journal-title":"Bone"},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02409454","volume":"33","author":"GA Rodan","year":"1981","unstructured":"Rodan GA, Martin TJ (1981) Role of osteoblasts in hormonal control of bone resorption- a hypothesis. Calcif Tissue Int 33:349\u2013351","journal-title":"Calcif Tissue Int"},{"key":"35_CR6","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1172\/JCI116422","volume":"91","author":"M Sahni","year":"1993","unstructured":"Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004\u20132011","journal-title":"J Clin Invest"},{"key":"35_CR7","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/endo.137.6.8641182","volume":"137","author":"C Vitte","year":"1996","unstructured":"Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324\u20132333","journal-title":"Endocrinology"},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/030097498441155","volume":"27","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27:38\u201341","journal-title":"Scand J Rheumatol"},{"key":"35_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1358\/mf.1999.21.8.794832","volume":"21","author":"JM Olmos","year":"1999","unstructured":"Olmos JM, De Vega T, Perera L, Riancho JA, Amado JA, Gonzalez Macias J (1999) Etidronate inhibits the production of IL-6 by osteoblast-like cells. Methods Find Exp Clin Pharmacol 21:519\u2013522","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"35_CR10","first-page":"6001","volume":"60","author":"GG Reinholz","year":"2000","unstructured":"Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001\u20136007","journal-title":"Cancer Res"},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PF, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374","journal-title":"J Clin Invest"},{"key":"35_CR12","first-page":"327","volume":"17","author":"MG Gandolfi","year":"1999","unstructured":"Gandolfi MG, Pugnaloni A, Mattioli-Belmonte M, Muzzarelli R, De Benedittis A, Mengucci P, Zucchini C, Tesei M, Caudarella R, Biag G (1999) Osteoblast behaviour in the presence of bisphosphonates: ultrastructural and biochemical in vitro studies. Clin Exp Rheumatol 17:327\u2013333","journal-title":"Clin Exp Rheumatol"},{"key":"35_CR13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gr\u00fcndker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680\u2013686","journal-title":"Biochem Biophys Res Commun"},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","volume":"25","author":"GI Im","year":"2004","unstructured":"Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105\u20134115","journal-title":"Biomaterials"},{"key":"35_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S8756-3282(98)00033-7","volume":"22","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455\u2013461","journal-title":"Bone"},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","volume":"19","author":"B Pan","year":"2004","unstructured":"Pan B, Farrugia AN, Bik To L, Findlay DM, Green J, Lynch K, Zannettino CW (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-\u03b1 converting enzyme (TACE). J Bone Miner Res 19:147\u2013154","journal-title":"J Bone Miner Res"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228\u20131236","journal-title":"J Clin Pharmacol"},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00198-005-1844-1","volume":"16","author":"P Mezquita-Raya","year":"2005","unstructured":"Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jimenez F, Munoz-Torres M (2005) The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 16:1368\u20131374","journal-title":"Osteoporos Int"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2004.02179.x","volume":"62","author":"KW Oh","year":"2005","unstructured":"Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol 62:92\u201398","journal-title":"Clin Endocrinol"},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00198-004-1699-x","volume":"16","author":"OS Indridason","year":"2005","unstructured":"Indridason OS, Franzson L, Sigurdsson G (2005) Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16:417\u2013423","journal-title":"Osteoporos Int"},{"key":"35_CR21","first-page":"3162","volume":"86","author":"P Szulc","year":"2001","unstructured":"Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162\u20133165","journal-title":"J Clin Endocrinol Metab"},{"key":"35_CR22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00223-004-0074-4","volume":"76","author":"BM Abdallah","year":"2005","unstructured":"Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jorgensen HR, Abrahamsen B (2005) Increased RANKL\/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 76:90\u201397","journal-title":"Calcif Tissue Int"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03040334","volume":"115","author":"A Fahrleitner-Pammer","year":"2003","unstructured":"Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai HP, Leb G, Obermayer-Pietsch B (2003) Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 115:291\u2013297","journal-title":"Wien Klin Wochenschr"},{"key":"35_CR24","first-page":"631","volume":"86","author":"WS Browner","year":"2001","unstructured":"Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631\u2013637","journal-title":"J Clin Endocrinol Metab"},{"key":"35_CR25","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","volume":"46","author":"M Ziolkowska","year":"2002","unstructured":"Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46:1744\u20131753","journal-title":"Arthritis Rheum"},{"key":"35_CR26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bone.2004.04.021","volume":"35","author":"G Amato","year":"2004","unstructured":"Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C (2004) High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 35:785\u2013791","journal-title":"Bone"},{"key":"35_CR27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","volume":"35","author":"LS Stilgren","year":"2004","unstructured":"Stilgren LS, Rettmer E, Eriksen EF, Hegedus L, Beck-Nielsen H, Abrahamsen B (2004) Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappa \u03b2 ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35:256\u2013265","journal-title":"Bone"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gut.2004.044370","volume":"54","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H (2005) The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54:479\u2013487","journal-title":"Gut"},{"key":"35_CR29","first-page":"S158","volume":"18","author":"S Sankaralingam","year":"2003","unstructured":"Sankaralingam S, Frost M, Fogelman I, Hampson G (2003) Early changes in serum osteoprotegerin (OPG) correlates with changes in bone mineral density following treatment with risedronate in post-menopausal women with osteoporosis (Abstract). J Bone Miner Res 18:S158","journal-title":"J Bone Miner Res"},{"key":"35_CR30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"35_CR31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kulik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"35_CR32","first-page":"2363","volume":"84","author":"P Ravn","year":"1999","unstructured":"Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention study. J Clin Endocrinol Metab 84:2363\u20132368","journal-title":"J Clin Endocrinol Metab"},{"key":"35_CR33","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","volume":"44","author":"S Christgau","year":"1998","unstructured":"Christgau S, Rosenquist C, Alexandersen P, Hannover Bjarnason N, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C (1998) Clinical evaluation of the serum crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290\u20132300","journal-title":"Clin Chem"},{"key":"35_CR34","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","volume":"13","author":"SL Greenspan","year":"1998","unstructured":"Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431\u20131438","journal-title":"J Bone Miner Res"},{"key":"35_CR35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","volume":"15","author":"A Rogers","year":"2000","unstructured":"Rogers A, Hannon RA, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause J Bone Miner Res 15:1398\u20131404","journal-title":"J Bone Miner Res"},{"key":"35_CR36","first-page":"268","volume":"4","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG\/RANKL\/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268\u2013275","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"35_CR37","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478\u20131487","journal-title":"J Bone Miner Res"},{"key":"35_CR38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C, Wie L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475\u20131480","journal-title":"J Clin Invest"},{"key":"35_CR39","first-page":"265","volume":"82","author":"HG Bone","year":"1997","unstructured":"Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E Polvino WJ (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265\u2013274","journal-title":"J Clin Endocrinol Metab"},{"key":"35_CR40","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1210\/endo.141.12.7840","volume":"141","author":"F Gori","year":"2000","unstructured":"Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768\u20134776","journal-title":"Endocrinology"},{"key":"35_CR41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","volume":"22","author":"P Lips","year":"2001","unstructured":"Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477\u2013501","journal-title":"Endocr Rev"},{"key":"35_CR42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","volume":"38","author":"SD Vasikaran","year":"2001","unstructured":"Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38:608\u2013623","journal-title":"Ann Clin Biochem"},{"key":"35_CR43","first-page":"230","volume":"108","author":"SL Greenspan","year":"1996","unstructured":"Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B (1996) Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 108:230\u2013238","journal-title":"Proc Assoc Am Physicians"},{"key":"35_CR44","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet\u00a0"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-0035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-005-0035-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-0035-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T10:14:22Z","timestamp":1586686462000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-005-0035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s00198-005-0035-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,25]]}}}